QGC006 program


The company intends to strengthen its pipeline by developing 2nd Generation products to manage the life cycle of products from the BAPAI technology. The objective of this program is to identify within this new class a QGC001 “back-up” product, which could become a “Best-in-class” product.

Quantum Genomics selected a second candidate-drug, the QGC006 product, ten times more powerful than the QGC001 product on Aminopeptidase A inhibition.